Arxx Therapeutics Secures NOK110

APIM Therapeutics AS announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a clinical trial to investigate ATX-101 in combination with platinum-based therapy in ovarian cancer. The trial...

Heimdall Power raises NOK 155 mill

The Norwegian Investment Company Saga Pure ASA has entered into an agreement to invest NOK 75 mill into Sarsia Seed portfolio company Heimdall Power AS to help accelerate the company’s growth strategy.  The total transaction was 155mNOK involving existing...